Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2

Clinical and Experimental Immunology

Volumn 116, Issue 3, 1999, Pages 486-492

  Zanussi, S ^a   Simonelli, C ^a   Bortolin, M T ^a   D'Andrea, M ^a   Crepaldi, C ^a   Vaccher, E ^a   Nasti, G ^a   Politi, D ^b   Barzan, L ^b   Tirelli, U ^a   De Paoli, P ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b Centro di Riferimento Oncologico ^*

Author keywords

HIV infection; IL 2 injections; Lymphocyte subsets; Lymphoid tissue; Peripheral blood cytokines

Indexed keywords

ANTIRETROVIRUS AGENT; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4;

ARTICLE; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; LYMPHOID TISSUE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; LYMPHOID TISSUE; MALE; MIDDLE AGED; PHENOTYPE;

EID: 0033035854     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00927.x     Document Type: Article

References (44)

1. Hellerstein MK, McCune JM. T cell turnover in HIV disease. Immunity 1997; 7:583-9.
2. Rosok B, Bostad L, Voltersvik P, Bjerknes R, Oloffson J, Asjo B, Brinchmann J. Reduced CD4 counts in blood do not reflect CD4 cell depletion in tonsillar tissue in asymptomatic HIV infection. AIDS 1996; 10:F35-F38.
3. Landay A, Bethel J, Schnittman S. Phenotypic variability of lymphocyte populations in peripheral blood and lymphnodes from HIV-infected individuals and the impact of antiretroviral therapy. AIDS Res Hum Retrovir 1998; 14:445-51.
4. Hufert FT, van Lunzen J, Janossy G, Bertram S, Schmitz J, Haller O, Racz P, von Laer D. Germinal centre CD4+ T cells are an important site of HIV replication in vivo. AIDS 1997; 11:849-57.
5. Zhang Z, Notermans D, Sedgewick G et al. Kinetics of CD4 repopulation of lymphoid tissues after treatment of HIV inlection. Proc Natl Acad Sci USA 1998; 95:1154-9.
6. Lederman M, Connick E, Landay A et al. Immunologic response associated with 12 weeks combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of ACTG protocol 315. J Infect Dis 1998; 178:70-79.
7. Mackall C, Hakim F, Gress R. T cell regeneration: all repertoires are not created equal. Immunol Today 1997; 18:245-511.
8. Mackall C, Fleisher T, Brown M et al. Distinctions between CD8+ and CD4+ regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997; 89:3700-7.
9. Watanabe N, De Rosa S, Cinelak A, Hoppe R, Herzemberg LA, Herzemberg LA, Roederer M. Long term depletion of naive T cells in patients treated for Hodgkin's disease. Blood 1997; 90:3662-72.
10. Autran B, Carcelain G, Li T et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
11. Tanaka T, Duke-Dohan JS, Kameoka J, Yaron A, Shlossman SF, Morimoto C. Enhancement of antigen-induced T cell proliferation by soluble CD26/DPPIV. Proc Natl Acad Sci USA 1994; 91:3082-6.
12. Schmitz T, Underwood R, Khiroya R, Bachovchin WW, Huber B. Potentiation of the immune response in HIV 1 individuals. J Clin Invest 1996; 97:1545-9.
13. June C, Bluestone J, Nadler L, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994; 15:321-31.
14. Roederer M, Dubs JG, Anderson MT, Raju PA, Herzemberg LA, Herzemberg LA. CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995; 95:2061-6.
15. Lafeuillade A, Chouraqui M, Hittinger G, Poggi C, Delbeke E. Lymph node expansion of CD4+ lymphocytes during antiretroviral therapy. J Infect Dis 1997; 176:1378-82.
16. Giorgi JV, Majehrowicz M, Johnson T, Hultin P, Matud J, Detels R. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS 1998; 12:1833-44.
17. Azuma M, Phillips JH, Lanier LL. CD28- T lymphocytes. Antigenic and functional properties. J Immunol 1993; 150:1147-59.
18. Caruso A, 5 Licenziati S, Canaris AD et al. Contribution of CD4+, CD8+CD28+, and CD8+CD28- T cells to CD3+ lymphocyte homeostasis during the natural course of HIV-1 infection. J Clin Invest 1998; 101:137-44.
19. Rinaldo C, Huang XL, Fan Z et al. High levels of anti HIV-1 memory cytotoxic T lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long term non-progressors. J Virol 1995; 69:5938-42.
20. Levy JA, Mackevicz CE, Barker E. Controlling HIV pathogenesis: the role of noncytotoxic anti HIV activity of CD8+ cells. Immunol Today 1996; 17:217-24.
21. Emery S, Lane H. Immune reconstitution in HIV infection. Curr Opin Immunol 1997; 9:568-72.
22. Kelleher A, Al-Harti L, Landay A. Immunological effects of anti-retroviral and immune therapies for HIV. AIDS 1997; 11 (Suppl. A):S149-s155.
23. Pakker N, Notermans D, De Boer R et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4:208-14.
24. Schwartz D, Skowron G, Merigan TC. Safety and effects of IL-2 plus zidovudine in asymptomatic individuals infected with HIV. J Acquir Immune Defic Syndr 1991; 4:11-23.
25. Kovacs JA, Vogel S, Albert JM et al. Controlled trial of IL-2 infusions in patients with HIV. New Engl J Med 1096; 335:1350-6.
26. De Paoli P, Zanussi S, Simonelli C. et al. Effects of subcutaneous IL-2 therapy on CD4 subsets and cytokine production in HIV+ subjects. J Clin Invest 1997; 100:2737-43.
27. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 4:1-19.
28. Simonelli C, Zanussi S, Sandri S et al. Concomitant therapy with s.c. IL-2 and zidovudine plus didanosine in patients with early stage HIV infection. J Acquir Immune Defic Syndr 1999; 20:20-27.
29. Barzan L, Carbone A, Saracchini S, Vaccher G, Tirelli U, Comoretto R. Nasopharyngeal lymphatic tissue hypertrophy in HIV infected patients. Lancet 1989; 1:42-43.
30. Valiante N, Trinchieri G. Identification of a novel signal transduction molecule on human cytotoxic lymphocytes. J Exp Med 1993; 178:1397-406.
31. Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell Scientific Publications, 1987: 110-47.
32. Kelleher AD, Roggensack M, Emery S, Carr A, French MA, Cooper DA. Effects of IL-2 therapy in asymptomatic HIV-infecled individuals on proliferate responses to mitogens, recall antigens and HIV-related antigens. Clin Exp Immunol 1998; 113:85-91.
33. Andersson J, Fehninger T, Patterson B, Pottage J, Agnoli M, Jones P, Behbahani M, Landay A. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS 1998; 12:F123-f129.
34. Lafeuillade A, Tamalet C, Poggi C, Pellegrino P, Tourres C, Izopet J. Antiretroviral effect of AZT-ddI combination on blood and lymph nodes. AIDS 1997; 11:67-72.
35. Walker R, Carter C, Muul L et al. Peripheral expansion of pre existing mature T cells is an important means of CD4+ T cell regeneration in HIV-infected adults. Nat Med 1998; 4:852-6.
36. Douek D, McFarland R, Keiser P et al. Changes in thymic function with age during the treatment of HIV infection. Nature 1998; 396:690-5.
37. Woods TC, Roberts BD, Butera ST, Folks TM. Loss of inducible virus in CD45RA naive cells after HIV-1 entry accounts for preferential viral replication in CD45RO memory cells. Blood 1997; 89:1635-41.
38. Spina CA, Prince HE, Richman DD. Preferential replication of HIV 1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. J Clin Invest 1997; 99:1555-64.
39. Zanussi S, Simonelli C, Bortolin MT, D'Andrea M, Comar M, Tirelli U, Giacca M, De Paoli P. Dynamics of provirus load and lymphocyte subsets after IL-2 treatment in HIV-infected patients. AIDS Res Hum Retrovir 1999; 15:97-103.
40. Leonard EJ, Yoshimura T. Human monocyte chemoattractant protein 1. Immunol Today 1990; 11:97-101.
41. Merigozzi M, De Filippi C, Biswas P et al. HIV infection superinduces MCP-1 production in human macrophages and in U937 promonocytic cells. In: 3rd ECEAR, Munich 1998. Abstr. 97-P3.
42. Weiss L, Si-Mohammed A, Giral P, Castiel P, Ledur A, Blondin C, Kazatchkine M, Haefner-Cavaillon N. Plasma levels of MCP-1, but not those of MIP-1α and RANTES correlate with virus load in HIV infection. J Infect Dis 1997; 176:1621-4.
43. Levy Y, Capitani C, Houhou S, Carriere I, Gaustauld JA, Viard JP, Aboulker JP. IL-2 in HIV patients: a randomized trial comparing sc, PEG, CIV IL-2 with AZT + ddI. In: 12th International Conference on AIDS, Geneva 1998. Abstr. 41229.
44. Davey RT, Chaitt DG, Piscitelli SC et al. Subcutaneous administration of IL-2 in HIV type 1-infected persons. J Infect Dis 1997; 175:781-9.